PODD241220C110000
- 0.00
- 0.000.00%
Insulet Newsroom
Insulet Adds Abbott's FreeStyle Libre 2 Plus to Omnipod 5's Compatibility Roster
CCORF Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $269
Insulet's Strategic Advancements and Market Positioning Drive Buy Rating
Citi Research's 'SMID Value' Rec List – CHWY, FHN, PODD, and More
Insulet To Present At Wolfe Research Healthcare Conference; Webcast At 12:00 PM ET
Insulet Announces Omnipod 5 System Is Now Compatible With Abbott's FreeStyle Libre 2 Plus Sensor In The U.S.
Express News | Insulet Announces Omnipod® 5 System Is Now Compatible With Abbott’s Freestyle Libre 2 Plus Sensor in the U.S.
Baptista Downgrades Insulet to Underperform
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Impressive Earnings May Not Tell The Whole Story For Insulet (NASDAQ:PODD)
Insulet's (NASDAQ:PODD) Solid Profits Have Weak Fundamentals
Insulet to Present at Upcoming Investor Conferences
Insulet Corporation (NASDAQ:PODD) Shares Could Be 35% Above Their Intrinsic Value Estimate
Zacks.com Featured Highlights Include NVIDIA, Insulet and Howmet Aerospace
Why Insulet (PODD) Is a Top Growth Stock for the Long-Term
PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up
Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $317
Insulet Is Maintained at Overweight by Morgan Stanley
Barclays Adjusts Price Target on Insulet to $234 From $220, Maintains Equalweight Rating
Express News | Insulet Corp : Citigroup Raises Target Price to $283 From $275